Paritaprevir

Structural formula
General
Non-proprietary name	Paritaprevir
other names	(2 R , 6 S , 12 Z , 13a R , 14a R , 16a S ) - N - (Cyclopropylsulfonyl) -6 - {[(5-methyl-2-pyrazinyl) carbonyl] amino} -5,16-dioxo- 2- (6-phenanthridinyloxy) -1,2,3,6,7,8,9,10,11,13a, 14,15,16,16a-tetradecahydrocyclopropa [ e ] pyrrolo [1,2- a ] [1 , 4] diazacyclopentadecine-14a (5 H ) -carboxamide ( IUPAC ); Veruprevir;
Molecular formula	C 40 H 43 N 7 O 7 S 1
External identifiers / databases
PubChem	68498031
ChemSpider	34999598
DrugBank	DB09297
Wikidata	Q16824572
Drug information
ATC code	J05 AX66
properties
Molar mass	765.88 g mol −1
safety instructions
	Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS hazard labeling ; no classification available
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Paritaprevir (formerly known as ABT-450 ) is a Acylsulfonamidinhibitor the NS3-4A- serine protease that of Abbott Laboratories for the treatment of hepatitis C is established. When given in combination with ritonavir and ribavirin for 12 weeks, genotype 1 hepatitis C virus is 95% eliminated after 24 weeks.

Paritaprevir is part of the combination preparations Viekira Pak and Technivie .

Individual evidence

↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
↑ Seng-Lai Tan, Yupeng He (Ed.): Hepatitis C: antiviral drug discovery and development . Caister academic press, Norfolk 2011, ISBN 9781904455783 , p. 210 ( Accessed April 28, 2014).

↑ Donald Jensen, Nancy Reau (ed.) Hepatitis C . Oxford University Press, New York 2013, ISBN 9780199844296 , p. 144 ( Accessed April 28, 2014).

↑ Abbott Announces Phase 3 Hepatitis C Program Details . In: Abbott company website . Abbott Laboratories. Retrieved April 28, 2014.

↑ Kris V. Kowdley, Eric Lawitz, Fred Poordad, Daniel E. Cohen, David R. Nelson, Stefan Zeuzem, Gregory T. Everson, Paul Kwo, Graham R. Foster, Mark S. Sulkowski, Wangang Xie, Tami Pilot-Matias , George Liossis, Lois Larsen, Amit Khatri, Thomas Podsadecki, Barry Bernstein: Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1 . In: New England Journal of Medicine . 370, No. 3, 2014, pp. 222-232. doi : 10.1056 / NEJMoa1306227 .

↑ TECHNIVIE ™ (ombitasvir, paritaprevir and ritonavir) tablets, for oral use. Full prescribing information . AbbVie Inc., North Chicago, IL 60064. Archived from the original on January 19, 2019. Retrieved July 28, 2015.

[NV-1] This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.

[Drugdisc-2] Seng-Lai Tan, Yupeng He (Ed.): Hepatitis C: antiviral drug discovery and development . Caister academic press, Norfolk 2011, ISBN 9781904455783 , p. 210 ( Accessed April 28, 2014).

[OUP-3] Donald Jensen, Nancy Reau (ed.) Hepatitis C . Oxford University Press, New York 2013, ISBN 9780199844296 , p. 144 ( Accessed April 28, 2014).

[AbbottPR-4] Abbott Announces Phase 3 Hepatitis C Program Details . In: Abbott company website . Abbott Laboratories. Retrieved April 28, 2014.

[KowdleyLawitz2014-5] Kris V. Kowdley, Eric Lawitz, Fred Poordad, Daniel E. Cohen, David R. Nelson, Stefan Zeuzem, Gregory T. Everson, Paul Kwo, Graham R. Foster, Mark S. Sulkowski, Wangang Xie, Tami Pilot-Matias , George Liossis, Lois Larsen, Amit Khatri, Thomas Podsadecki, Barry Bernstein: Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1 . In: New England Journal of Medicine . 370, No. 3, 2014, pp. 222-232. doi : 10.1056 / NEJMoa1306227 .

[6] TECHNIVIE ™ (ombitasvir, paritaprevir and ritonavir) tablets, for oral use. Full prescribing information . AbbVie Inc., North Chicago, IL 60064. Archived from the original on January 19, 2019. Retrieved July 28, 2015.